Table 1.
Studies considered in systematic review and meta-analysis
| Endpoint | No. of endpoints within studies | No. of studies |
|---|---|---|
| All studies | ||
| Ischaemic heart disease | 38 | 38 |
| Other heart | 27 | 16 |
| Cerebrovascular disease | 32 | 31 |
| Other cardiovascular disease | 12 | 10 |
| All cardiovascular disease* | 105 | 86 |
| All studies/endpoints† | 157 | 93 |
| Studies with mean bias score ≥4 | ||
| Ischaemic heart disease | 17 | 17 |
| Other heart | 13 | 7 |
| Cerebrovascular disease | 14 | 14 |
| Other cardiovascular disease | 8 | 7 |
| All cardiovascular disease* | 48 | 34 |
| All studies/endpoints† | 75 | 34 |
| Studies with mean quality score ≥4 | ||
| Ischaemic heart disease | 4 | 4 |
| Other heart | 1 | 1 |
| Cerebrovascular disease | 4 | 4 |
| Other cardiovascular disease | 4 | 4 |
| All cardiovascular disease* | 10 | 9 |
| All studies/endpoints† | 15 | 9 |
*
Considering maximal set of all non-overlapping endpoints within a study.
†
Considering maximal set of all non-overlapping endpoints within a study, as well as all non-overlapping endpoints within each of the four specific cardiovascular disease subtypes (ischaemic heart disease, other heart, cerebrovascular disease, other cardiovascular disease).